Clinical Trials Directory
We are doing this study to find out if an experimental drug called brepocitinib (the study drug) is a safe and effective option people with non-infectious uveitis (NIU).
If you choose to join this study, we will ask you questions about:
- Your life at home
- Your life at school
- Your medical needs
We are doing this study to find the most effective, safe dose of an experimental drug called quizartinib (the study drug) for people with acute myeloid leukemia (AML) who do not have a FLT3-ITD mutation and who have not completed any treatment for their disease.
We are doing this study to find out how safe and effective it is to give people with recurrent glioblastoma two infusions of an experimental drug called lerapolturev (the study drug) in residual disease (within tumor margins) after surgery. After these two doses, we will give further doses of the study drug as injections in the subcutaneous area (under the skin) around the lymph nodes of the head and neck. We also want to know how well the study drug works compared to lomustine, which is a standard form of chemotherapy (drug used to kill cancer cells).
We are doing this study to find out if a personalized exercise program designed for lung cancer patients can help with recovery from lung surgery. The study's exercise program is delivered over the phone.
We created this registry for people with rare breast tumors to help us learn more about them and how to better treat people in the future.
We are doing this study to find out if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for people with metastatic pancreatic ductal adenocarcinoma (PDAC). We want to see how well the study drug works compared to the standard chemotherapy regimen for PDAC.
We are doing this study to learn more about the long-term effectiveness of an approved medicine that is prescribed for the treatment of EoE. We want to know how will dupilumab (Dupixent®) works over time when EoE patients and their doctors choose it as therapy. Dupilumab was approved by the FDA in May 2022 to treat EoE and was the first drug approved for this purpose.